title: [A comparaison between the total PSA, the Gleason score and the bone scintiscan results for different age groups].
abstract: The aim of the study is to compare de results of the bone scintigraphy of prostate cancer patients in different age groups with their total PSA (PSAt) and with their histopathological test results. MATERIALS AND METODS: Of the 180 patients with prostate cancer who were analyzed by Scintiscan in the last five years in our laboratory, 86 have a known PSAt value, and of these, 55 have a known Gleason Score. The 180 patients were divided into three age groups: (1) < or equal 60 years; (2) 60-70 years and (3) >70 years. The 86 patients with a known PSAt were also divided into five groups according to their PSAt value and the 55 patients with a known Gleason Score were divided in three groups. The scintigraphy results included all the patients in 3 groups, according to the presence, the absence or the likelihood of having bone metastasis. The 33 patients with proven bone metastasis were divided, according to their numbers, into the four Soloway groups.
  
  
  RESULTS
  Among the patients with PSAt >20 ng/mL, considered high risk for bone metastases, according to the Recomandations of CCAF, 21 (32.81%) of the 64 patients do not show the presence of bone metastases. For PSAt >50 ng/mL, all 5 patients <60 years of age have metastases, while only 15 (62.5%) of the 24 patients over 70 years old have metastases and 1 (4%) has low likelihood. 6 (21.42%) of the 28 patients with PSAt > sau egal 100 ng/mL do not have metastases. 10 (43.4 %) of the 23 patients with a Gleason Score <7, considered low risk, do have metastases (6 patients--26%) or low probability of metastases (4 patients--17.4%).
  
  
  CONCLUSIONS
  Our study confirms that the probability of bone metastasis for a high PSAt value is reversely proportional to age. In our study there is no direct correlation between Gleason Score and the bone scan results.
authors.affiliation: Universităţii de Medicină şi Farmacie Gr.T. Popa Iaşi Spitalul Clinic Judeţean de Urgenţe Sf. Spiridon Iaşi, Laboratorul de Medicină Nucleară.
authors.forename: Daniela
authors.initials: D
authors.lastname: Rusu
authors.forename: Valeriu
authors.initials: V
authors.lastname: Rusu
authors.forename: Cipriana
authors.initials: C
authors.lastname: Stefănescu
authors.forename: Maria
authors.initials: M
authors.lastname: Rusu
authors.forename: Irena
authors.initials: I
authors.lastname: Răileanu
authors.forename: Ana Maria
authors.initials: AM
authors.lastname: Stătescu
mesh_terms: D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood*; D001859:Bone Neoplasms / Q000000981:diagnostic imaging* / Q000556:secondary*; D001842:Bone and Bones / Q000000981:diagnostic imaging*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging / Q000379:methods; D011237:Predictive Value of Tests; D011379:Prognosis; D017430:Prostate-Specific Antigen / Q000097:blood*; D011471:Prostatic Neoplasms / Q000097:blood / Q000000981:diagnostic imaging* / Q000473:pathology*; D011877:Radionuclide Imaging; D012720:Severity of Illness Index
chemical_list: D014408:Biomarkers, Tumor; D017430:Prostate-Specific Antigen